Q2 EARNINGS: JNJ device growth still slow but improving
This article was originally published in Clinica
Executive Summary
Johnson & Johnson is trying to take advantage of its size and breadth to revive revenues from its medical device business, which saw Q2 figures take a hit from the group’s streamlining activities and from ongoing currency headwinds.